3/5
04:18 pm
ctnm
Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones [Yahoo! Finance]
High
Report
Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones [Yahoo! Finance]
3/5
04:05 pm
ctnm
Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
Neutral
Report
Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
3/3
04:05 pm
ctnm
Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference
Medium
Report
Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference
3/2
10:03 am
ctnm
Beat the Market the Zacks Way: Contineum Therapeutics, Suzano, PepsiCo in Focus [Yahoo! Finance]
Medium
Report
Beat the Market the Zacks Way: Contineum Therapeutics, Suzano, PepsiCo in Focus [Yahoo! Finance]
2/18
04:05 pm
ctnm
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2/14
01:32 am
ctnm
Contineum Therapeutics (NASDAQ:CTNM) was upgraded by analysts at
Wall St
Low
Report
Contineum Therapeutics (NASDAQ:CTNM) was upgraded by analysts at
Wall St
1/28
04:05 pm
ctnm
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
1/27
10:42 am
ctnm
Contineum Therapeutics, Inc. (NASDAQ:CTNM) surges 10%; retail investors who own 51% shares profited along with institutions [Yahoo! Finance]
Medium
Report
Contineum Therapeutics, Inc. (NASDAQ:CTNM) surges 10%; retail investors who own 51% shares profited along with institutions [Yahoo! Finance]
1/10
01:07 am
ctnm
Contineum Therapeutics (NASDAQ:CTNM) was downgraded by analysts at
Wall
Low
Report
Contineum Therapeutics (NASDAQ:CTNM) was downgraded by analysts at
Wall
1/8
08:02 am
ctnm
Contineum Therapeutics (NASDAQ:CTNM) had its "equal weight" rating reaffirmed by analysts at Morgan Stanley. They now have a $14.00 price target on the stock, down previously from $23.00.
Low
Report
Contineum Therapeutics (NASDAQ:CTNM) had its "equal weight" rating reaffirmed by analysts at Morgan Stanley. They now have a $14.00 price target on the stock, down previously from $23.00.
12/21
01:08 am
ctnm
Contineum Therapeutics (NASDAQ:CTNM) was upgraded by analysts at
Wall St
Low
Report
Contineum Therapeutics (NASDAQ:CTNM) was upgraded by analysts at
Wall St
12/13
01:10 am
ctnm
Contineum Therapeutics (NASDAQ:CTNM) was downgraded by analysts at
Wall
Medium
Report
Contineum Therapeutics (NASDAQ:CTNM) was downgraded by analysts at
Wall
12/12
01:57 am
ctnm
Contineum Therapeutics stock drops as company prices upsized $90 million offering [Seeking Alpha]
Medium
Report
Contineum Therapeutics stock drops as company prices upsized $90 million offering [Seeking Alpha]
12/11
10:24 pm
ctnm
Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering
Medium
Report
Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering
12/11
04:05 pm
ctnm
Contineum Therapeutics Announces Proposed $75.0 Million Public Offering
Medium
Report
Contineum Therapeutics Announces Proposed $75.0 Million Public Offering